Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have reduced susceptibility to neutralization by vaccines. In response to the constantly updated variants, a global vaccine booster vaccination program has been launched. In this study, we detected neutralizing antibody levels against wild-type (WT), Delta (B1.617.2), and Omicron BA.1 viruses in serum after each dose of CoronaVac vaccination. We found that booster vaccination significantly increased the levels of neutralizing antibodies against WT, Delta, and Omicron BA.1. Compared with only one vaccination, neutralizing antibody levels increased by 19.2–21.6-fold after a booster vaccination, whilst two vaccinations only produced a 1.5–3.4-fold increase. Our results support the conclusion that the CoronaVac vaccine booster can increase neutralizing antibody levels and cross-reactivity and enhance the body’s ability to effectively resist the infection of new coronavirus variants, emphasizing the need for booster vaccination.

[1]  R. Bull,et al.  Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission , 2022, Reviews in medical virology.

[2]  William T. Harvey,et al.  SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway , 2022, Nature Microbiology.

[3]  F. Baldanti,et al.  Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant , 2022, Nature Communications.

[4]  Xinquan Wang,et al.  Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction , 2022, Cell Research.

[5]  M. Hoffmann,et al.  Omicron: Master of immune evasion maintains robust ACE2 binding , 2022, Signal Transduction and Targeted Therapy.

[6]  K. Swanson,et al.  Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine , 2022, Nature Communications.

[7]  Qi Qin,et al.  Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant , 2022, Cell Research.

[8]  Gheyath K Nasrallah,et al.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.

[9]  D. Lavillette,et al.  An mRNA vaccine candidate for the SARS-CoV-2 Omicron variant , 2022, bioRxiv.

[10]  E. Quiros-Roldan,et al.  Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review , 2022, International journal of molecular sciences.

[11]  Po-Cheng Chiang,et al.  Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants , 2022, bioRxiv.

[12]  H. Blum,et al.  Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern , 2022, Nature Medicine.

[13]  S. Subramaniam,et al.  SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex , 2022, Science.

[14]  Xiaozhong Peng,et al.  Circular RNA vaccines against SARS-CoV-2 and emerging variants , 2022, Cell.

[15]  G. Wei,et al.  Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance , 2022, J. Chem. Inf. Model..

[16]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[17]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2022, Cell.

[18]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[19]  Saniya M. Ansari,et al.  Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective , 2021, Journal of medical virology.

[20]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[21]  G. Screaton,et al.  Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum , 2021, The Lancet.

[22]  Wen Zheng,et al.  Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials , 2021, The Lancet Infectious Diseases.

[23]  P. Kaleebu,et al.  Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts , 2021, International Journal of Infectious Diseases.

[24]  G. Luo,et al.  Omicron variant (B.1.1.529) of SARS‐CoV‐2, a global urgent public health alert! , 2021, Journal of medical virology.

[25]  J. Lopez Bernal,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.

[26]  M. Davenport,et al.  Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.

[27]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[28]  X. Wang,et al.  A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2 , 2021, medRxiv.

[29]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[30]  William T. Harvey,et al.  Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination , 2021, medRxiv.

[31]  S. Madhi,et al.  Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum , 2021, Cell.

[32]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[33]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[34]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[35]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[36]  Vineet D. Menachery,et al.  Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.

[37]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[38]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[39]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[40]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[41]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[42]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[43]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.